semorinemab
mAbexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jun 30, 2016 (NCT02820896)
Timeline
Indications
Studied for
Mechanism of action
- Microtubule-associated protein tauINHIBITOR
Microtubule-associated protein tau inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4298093 ↗
Also known as
- ro7105705
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03828747 | Phase 2 | Jan 30, 2019 | Genentech, Roche |
| NCT03289143 | Phase 2 | Oct 4, 2017 | Genentech |
| NCT02820896 | Phase 1 | Jun 30, 2016 | Genentech, Roche |
Showing 3 of 3 trials
Page 1 / 1